Biosyent Inc (OTCPK:BIOYF)
$ 7.35 0.16 (2.23%) Market Cap: 88.74 Mil Enterprise Value: 68.12 Mil PE Ratio: 16.90 PB Ratio: 3.45 GF Score: 98/100

Q4 2022 Biosyent Inc Earnings Call Transcript

Mar 21, 2023 / NTS GMT
Release Date Price: $5.32
RenÃ;C. Goehrum
BioSyent Inc. - Chairman, CEO & President

© -

Hello, and welcome to the BioSyent, Inc. Q4 and Full Year Fiscal 2022 Results Presentation. My name is René Goehrum, and I'm the President and CEO of the company. Before I start the presentation, I want to bring your attention to our disclaimer on forward-looking statements. And I'll jump right into the presentation by looking at the Q4 revenue, EBITDA and net income after tax.

So you can see sales were just short of $7.5 million for the quarter. That was up 3% to the year ago. And I want to go into a little bit of detail to help you follow the moving parts on revenue. So in the quarter, the Canadian Pharmaceutical business was up 13% to the year ago. The International Pharma business down 63%, and the Legacy Business down 87% in the quarter. You'll recall that late last year, we discontinued products effective the beginning of 2022, I should say late last year as in 2021, the comparable period. And so when we're looking at revenue for Canada and overall, it is useful to also compare to a continuing business basis. And

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot